The hallmark of chronic myeloid leukemia (CML) is the chimeric tyrosine kinase oncogene bcr ± abl. Since expression of bcr ± abl mRNA frequently increases with disease progression and a duplication of the Philadelphia chromosome (harbouring the bcr ± abl hybrid locus) represents the most frequent karyotypic abnormality in acute phase CML, we hypothesized that the level of BCR ± ABL protein may aect the disease phenotype. Therefore, the biological eects of high and low levels of BCR ± ABL expression were compared in growth factor-dependent and -independent myeloid and lymphoid cell lines. Our results demonstrated that low levels of BCR ± ABL were sucient to render these cell lines growth factor independent and tumorigenic, but higher levels were mandatory for additional protection against apoptotic stimuli. The provision of growth factor or an activated ras oncogene did not aord the same degree of protection as high levels of BCR ± ABL and there were qualitative dierences between the survival signals mediated by BCR ± ABL and Bcl-2. These results have enabled us to establish a dosedependent hierarchy of BCR ± ABL induced biological eects, thus distinguishing the activation of pathways mediating protection from cytokine withdrawal from those protecting against other apoptotic stimuli.
Introduction
Chronic myeloid leukemia (CML) is characterised by the creation of a chimeric tyrosine kinase, bcr ± abl, which arises as the consequence of a reciprocal translocation which fuses the 5' sequences of the bcr gene on chromosome 22 to most of the c-abl protooncogene on chromosome 9 (Groen and Heisterkamp, 1987) . A heightened tyrosine kinase activity of the bcr ± abl fusion protein compared to its normal c-abl counterpart is responsible for the transforming ability of the oncogene (Konopka and Witte, 1985) . Clinically, the disease manifests as an initially indolent myeloproliferative disease (the chronic phase) which is overtaken some years later by an aggressive acute leukemia (the acute phase).
Retrovirally-mediated gene transfer experiments in which murine bone marrow cells were transduced with a bcr ± abl cDNA demonstrated that BCR ± ABL protein could initiate transformation in primary cells (Daley et al., 1990; Elefanty et al., 1990; Kelliher et al., 1990) . The stochastic nature of the tumours in these murine models was consistent with the requirement for additional synergistic mutations for transformation, and in this way mimicked disease progression in CML. A distinct disease state corresponding to the chronic phase of human CML was lacking, however. In vitro studies demonstrated that expression of bcr ± abl in cytokine-dependent immortalized murine hematopoietic cell lines relieved them of their requirements for exogenous growth factors, thereby rendering them tumorigenic (Daley and Baltimore, 1988; Hariharan et al., 1988) . Several studies subsequently demonstrated that bcr ± abl also protected these cell lines from apoptosis induced by irradiation and cytotoxic drugs (Bedi et al., 1995; Cortez et al., 1995; Nishii et al., 1996) . It is noteworthy that all existing CML cell lines were established from patients in the acute phase of the disease and were also factor independent, tumorigenic and relatively resistant to apoptosis (Keating, 1987; McGahon et al., 1994) . However, these cell lines fail to accurately re¯ect the in vitro behavior of primary cells from patients in the chronic phase of CML. In most cases, CML progenitor cells are neither growth factor independent nor resistant to apoptotic stimuli (Amos et al., 1995; Albrecht et al., 1996) , although this latter point has been disputed (Bedi et al., 1994 (Bedi et al., , 1995 .
One explanation for the discordant observations from chronic phase CML progenitors and cells from the actue phase or bcl ± abl transformed murine cell lines was that the latter harboured additional mutations which synergized with BCR ± ABL. Whilst the nature of these complementary mutations has remained largely obscure, we were intrigued by the possibility that the level of BCR ± ABL protein might be one factor which in¯uenced the disease phenotype. Several lines of evidence argued in favour of this possibility. Firstly, the persistence of BCR ± ABL expression through all stages of CML suggested that there was an ongoing requirement for the protein. In fact, in many cases, expression of bcr ± abl mRNA actually increased with disease progression (Collins et al., 1984; Andrews and Collins, 1987; Gaiger et al., 1995) and a duplication of the Philadelphia chromosome (harbouring the bcr ± abl hybrid locus) represented the most frequent karyotypic abnormality in acute phase CML (Kantarjian et al., 1987) . Indeed, in CML derived cell lines there were often multiple copies or ampli®cation of the Philadelphia chromosome in addition to many other acquired karyotypic changes (Keating, 1987) . Moreover, the in vivo and in vitro murine model systems studied thusfar employed retroviral sequences which led to BCR ± ABL expression at relatively high levels, comparable to those in the acute phase CML cell lines (Elefanty et al., 1990) . Therefore, we compared the biological eects of two bcr ± abl expression vectors ± one, the MPZen(bcr ± abl) retroviral vector, which we had shown previously could direct high level BCR ± ABL expression in hematopoietic cells (Hariharan et al., 1988; Elefanty et al., 1990) and the second, a bcr ± abl expression vector regulated by the human bcr promoter. We reasoned that this latter construct might lead to a lower expression level more closely approximating that of BCR ± ABL in chronic phase CML. We extended our studies to include cell lines expressing a constitutively activated ras oncogene or a dominant-negative ras, since it has been argued that activation of the ras/MAPK pathway is important in BCR ± ABL-mediated transformation and resistance to apoptosis (Pendergast et al., 1993; Sakai et al., 1994; Cortez et al., 1995 Cortez et al., , 1996 Goga et al., 1995; Raitano et al., 1995; Sawyers et al., 1995) .
We have demonstrated a marked dose dependence in the biological consequences of BCR ± ABL expression. Low levels of BCR ± ABL were sucient, in the setting of these immortalised cell lines, to remove cytokine requirements and render the cells tumorigenic, but high levels were mandatory for protection against other apoptotic stimuli. The provision of growth factor or expression of an activated ras oncogene did not oer the same protection as high expression of BCR ± ABL. Although high levels of BCR ± ABL increased Bcl-2 protein levels, there were subtle dierences in the eects of the two proteins. These results have enabled us to distinguish bcr ± abl activated pathways mediating protection from cytokine withdrawal from those protecting against other apoptotic stimuli.
Results

Generation of hematopoietic cell lines expressing high or low levels of BCR ± ABL
The two vectors used to examine the biological consequences of bcr ± abl expression are shown in Figure 1a . In the MPZen(bcr ± abl) vector (Hariharan et al., 1988) , expression of the bcr ± abl cDNA was directed by the Moloney murine leukemia virus long terminal repeat. In the bcr ± bcr ± abl construct, 4 kb of human bcr sequence provided a promoter which might direct a lower level of BCR ± ABL expression, perhaps similar to that seen in chronic phase CML. To evaluate these constructs, we generated stable BCR ± ABLexpressing transfectants in four hematopoietic cell lines representing examples of growth factor-dependent and -independent myeloid (FDC-P1 and M1 cells) and lymphoid cell lines (CTLL-2 and 3D0-54.8).
It had been shown previously that bcr ± abl and v-abl oncogenes relieved FDC-P1 cells of their requirements for exogenous IL-3 or GM-CSF (Hariharan et al., 1988) . Factor independent lines were readily derived from FDC-P1 cells transfected with either bcr ± abl expression vector, suggesting that biologically active protein was produced from both constructs. Six independent clones bearing the MPZen(bcr ± abl) vector (denoted FD.rv210) and the bcr ± bcr ± abl vector (denoted FD.bcr210) were used in subsequent studies.
BCR ± ABL expression in these cell lines was con®rmed by indirect immuno¯uorescence using a monoclonal antibody (24-21) directed against the Cterminus of ABL (Schi-Maker et al., 1986) and imaged with a confocal microscope. We demonstrated the correct cytoplasmic localization of immunoreactive BCR ± ABL protein in both FD.rv210 and FD.bcr210 clones ( Figure 1b ). As expected from previous studies (van Etten et al., 1989) , the low level of endogenous c-ABL protein was not detectable in parental FDC-P1 cells by immuno¯uorescence (Figure 1b) . Furthermore, it appeared that the FD.rv210 clones expressed higher amounts of BCR ± ABL protein than the FD.bcr210 clones. Quanti®cation of the¯uorescence (using the SCANWARE software package) indicated that the FD.rv210 clones expressed twice as much BCR ± ABL protein per cell as the FD.bcr210 clones ( Table 1) . As a sensitive, independent means of evaluating BCR ± ABL expression of the FDC-P1 clones on a`per cell' basis, we employed a¯ow cytometric technique (Jacob et al., 1991) , which has been used by ourselves and others to quantify the expression of intracellular proteins (see Yin et al., 1994; Huang et al., 1997 for examples) . Figure 1c shows a representative¯ow cytometric pro®le from untransfected FDC-P1 cells (representing background staining) compared with pro®les obtained from FD.bcr210 and FD.rv210 clones. It can be seen that the FD.rv210 clone expressed higher levels of BCR ± ABL protein than the FD.bcr210 clone, corroborating the results obtained by indirect immunouorescence. This was a consistent ®nding for the six clones of each type evaluated (see Table 1 ) and there was a strong correlation between the results obtained using both methods (correlation co-ecient of 0.92). We also performed immunoblots of cell lysates from FD.bcr210 and FC.rv210 clones to demonstrate that a BCR ± ABL protein of the correct size was produced by both vectors (data not shown). Hybridization of immunoblots with an anti-phosphotyrosine antibody revealed tyrosine phosphorylation of many intracellular proteins in both FD.bcr210 and FD.rv210 clones, consistent with the biological requirement for kinase activity to render the clones growth factor-independent.
To examine the biology of BCR ± ABL in a context where selection for growth factor independence was not relevant, we produced bcr210 and rv210 transfectants in the monocytic line M1 and the T cell hybridoma line 3D0-54.8. The same¯ow cytometric method was employed to quantify the levels of BCR ± ABL expression. As with the FDC-P1 clones, we again found that the rv210 clones expressed more BCR ± ABL protein than the bcr210 clones. In M1 cells, BCR ± ABL protein was expressed eightfold higher in the rv210 clones compared to the bcr210 clones and in 3D0-54.8 cells the rv210 clones expressed approximately sixfold more BCR ± ABL than the bcr210 clones ( Figure 1c and Table 1 ). However, we found that BCR ± ABL expression was lost during in vitro culture (often within 2 ± 3 weeks) from most M1 and 3D0-54.8 clones even though antibiotic selection was maintained, presumably because the factor-independent parental cells did not provide an enviroment which continuously selected for retention of BCR ± ABL expression. Alternatively, BCR ± ABL may have been growth inhibitory in these cells, selecting for variants that had lost expression of the gene. Consequently, experiments were performed using recently thawed aliquots of cells in which uniform expression of BCR ± ABL was con®rmed by¯ow cytometric analysis immediately prior to use. Three independent clones of each cell line were evaluated for each construct except for 3D0-54.8 cells transfected with the MPZen(bcr ± abl) vector (3D0.rv210 clones), where only one BCR ± ABL expressing pool was obtained from several transfections. Four clones derived from this pool were examined, but Southern blot analysis suggested that they were siblings (data not shown).
Finally, we examined the eects of BCR ± ABL expression in the IL-2-dependent T cell line CTLL-2. Clones maintained in the presence of IL-2 rapidly lost BCR ± ABL expression, similar to the M1 and 3D0-54.8 cell lines. In the absence of IL-2, factorindependent cells which stably expressed higher levels of BCR ± ABL than the parental clone emerged from each of ®ve CTLL.rv210 and CTLL.bcr210 clones examined. Unlike the other cell lines examined, the amount of BCR ± ABL protein in the CTLL.rv210 clones was only slightly higher than in the CTLL.bcr210 clones ( Figure 1c and Table 1 ). This might indicate that the threshold level of BCR ± ABL required to render CTLL-2 cells cytokine-independent was higher than that for FDC-P1 cells, thus selecting for CTLL.bcr210 clones which expressed nearly as much protein as the CTLL.rv210 clones. Alternatively, the bcr promoter may have been intrinsically more active in these cells.
Clones expressing lower levels of BCR ± ABL are more responsive to growth factors
Although both bcr ± abl expression vectors rendered FDC-P1 and CTLL-2 cells factor independent, we wished to determine whether there were dierences in cytokine responsiveness which correlated with the amount of BCR ± ABL protein. The growth rates for six FD.bcr210 and six FD.rv210 clones were compared in the absence and presence of IL-3. Although there was variation between clones, ®ve of six FD.bcr210 clones responded to IL-3 with a 425% increase in growth while only two of six FD.rv210 clones grew more rapidly in the presence of cytokine (Figure 2a ). When the growth of these clones was compared in agar, the level of BCR ± ABL protein was found to in¯uence colony size rather than clonogenicity. In the absence of IL-3, the colonies generated by the FD.bcr210 cell lines were smaller (3550+340 cells/colony) than those generated by the FD.rv210 clones (7490+1290 cells/colony) ( Table 2 ). The FD.bcr210 clones responded to IL-3 with a 59% increase in cell number but FD.rv210 clones grown in the presence of IL-3 were only 9% larger on average. When growth rates of BCR ± ABL expressing CTLL-2 clones were compared in the presence and absence of IL-2, all three CTLL.bcr210 and one of three CTLL.rv210 clones evaluated remained responsive to cytokine ( Figure 2b ). The greater similarity of the growth rates between the sets of CTLL-2 clones may have re¯ected their similar BCR ± ABL expression levels. One mechanisms by which BCR ± ABL could abrogate growth factor-dependence in FDC-P1 and CTLL-2 cells was via an autocrine loop. However, when 20-fold concentrated conditioned media (CM) from BCR ± ABL-expressing FDC-P1 or CTLL-2 clones were assayed, no IL-3 or GM-CSF bioactivity was detected in FCD-P1 CM and no IL-2 bioactivity was found in CTLL-2 CM. A linear relationship was demonstrated between the number of cells plated in agar and the number of colonies observed for the FD.bcr210 and FD.rv210 clones (data not shown), further arguing against an autocrine mechanism for growth factor independence.
FDC-P1 cells expressing low or high levels of BCR ± ABL are tumorigenic in mice FD.bcr210 and FD.rv210 clones were transplanted into syngeneic mice to determine whether the level of Relative¯uorescence intensity in arbitrary units of cytoplasmic BCR ± ABL protein calculated by subtracting background fluorescence in untransfected cells. All values were derived from¯ow cytometry except for FDC-P1 Expt 1, which represents data quanti®ed from the confocal microscope. Results represent the mean and standard deviation of 3 ± 6 clones carrying the MPZen (bcr ± abl) retrovirus (rv210) or the bcr ± bcr ± abl expression vector (bcr210). The rv210 and bcr210 data were compared using a t-Test. The probability of the results being dierent is indicated. nd, not determined. No P value could be calculated for the CTLL clones in the absence of a measurable standard deviation. BCR ± ABL protein in¯uenced tumour growth or phenotype. As a comparison, we also tested FCD-P1 clones expressing high levels of a constitutively activated Harvey-ras gene (denoted FD.rasV12), which had been selected for IL-3 independence. This oncogene was studied since ras has been implicated in both cytokine receptor signalling (Ihle, 1996) and BCR ± ABL mediated transformation (Pendergast et al., 1993; Goga et al., 1995; Raitano et al., 1995; Sawyers et al., 1995) . Intravenous injection of parental FDC-P1 cells did not lead to tumours in recipient mice during a six month observation period. In contrast, recipients of 4/4 FD.rv210 clones and 3/4 FD.bcr210 clones developed tumours from 3 ± 10 weeks after injection (Table 3) . Disease latency and phenotype was similar in all recipients of BCR ± ABL-expressing FDC-P1 cells. Hematopoietic organs were in®ltrated, leading to splenomegaly and replacement of sternal and vertebral bone marrow by tumour cells, usually associated with extradural compression of the spinal cord. BCR ± ABL-expressing FDC-P1 cells were readily grown in tissue culture from cell suspensions from the spleens of sick animals. In all six cases analysed (representing recipients of 3 FD.bcr210 and 3 FD.rv210 clones), the level of BCR ± ABL protein in the tumour paralleled that found in the original transplanted cell line, implying that, in this system, tumour growth did not select for cells with higher BCR ± ABL expression.
Although the FD.rasV12 clones grew more slowly than the BCR ± ABL expressing clones in liquid culture in the absence of IL-3 (data not shown), they formed the most rapidly growing tumours in recipient mice. The diseases induced by BCR ± ABL expressing FCD-P1 clones and FD.rasV12 clones were similar, but there were some notable dierences. Mice transplanted with FD.rasV12 clones more frequently presented with hindlimb paralysis secondary to spinal cord compression. Liver and lung in®ltration were less frequent and less extensive in FD.rasV12 recipient mice and it was less common for these mice to exhibit blast cells in the peripheral blood.
High levels of BCR ± ABL protein are necessary for protection against apoptosis
Since it had been demonstrated that BCR ± ABL protected cells against apoptosis (Bedi et al., 1994; McGahon et al., 1994; Bedi et al., 1995; Cortez et al., 1995; Nishii et al., 1996) , we assessed whether this was in¯uenced by the level of protein. Survival of FD.bcr210, FD.rv210 and FD.rasV12 clones exposed to increasing doses of g-irradiation was compared to parental FDC-P1 cells and FDC-P1 cells transfected with the human bcl-2 gene (FD.bcl2), which was known to protect against radiation (Strasser et al., 1991) . As shown in Figure 3a , the FD.rv210 clones were markedly resistant to irradiation as assessed by cell viability at 72 h post-irradiation, surviving nearly as well as FD.bcl2 cells. In contrast, cells from FD.bcr210 clones, FD.rasV12 clones and the parental FDC-P1 cell line were killed by exposure to 30 Gy. The FD.rasV12 clones died more rapidly than parental cells at intermediate doses of radiation, a defect corrected by maintaining the FD.rasV12 clones in the presence of IL-3. This suggested that Ras alone was unable to provide protection against apoptosis in response to DNA damage. On the other hand, including IL-3 in the culture medium did not further augment the survival of FD.bcr210 or FD.rv210 clones (data not shown).
Similar results were obtained when the FDC-P1 clones were grown in low serum levels or exposed to staurosporine, an inhibitor of tyrosine and serine/ threonine kinases (Figure 3b and c) . FCD-P1 cells, FD.bcr210 clones and FD.rasV12 clones underwent apoptosis but the FD.rv210 clones displayed enhanced survival, comparable to the FD.bcl2 cells. Survival of FD.rasV12 clones in low serum was again augmented by the inclusion of IL-3. Cell lines were grown in agar in the presence or absence of 1000 U/ ml recombinant mIL-3 for 7 days. Ten sequential colonies were picked from each of three cultures for each cell line and the mean colony size estimated. Colony size was similar in cultures seeded at 50 ± 300 cells/ml for all clones. Numbers represent the mean+standard deviation of cell numbers per colony. N.A.; not applicable These data on FDC-P1 cells suggested that growth factor independence could be distinguished from survival following exposure to other apoptotic stimuli, with a higher threshold of BCR ± ABL protein required for the latter. Consistent with this prediction, protection against a range of apoptotic stimuli in BCR ± ABLexpressing M1, 3D0-54.8 and CTLL-2 clones also depended on the level of protein expressed. M1.rv210 and 3D0.rv210 clones were resistant to g-radiation, serum deprivation and, in the case of the 3D0.rv210 cells, dexamethasone, whilst M1.bcr210 and 3D0.bcr210 clones were not protected (Figure 4) . Since 3D0-54.8 cells express the Fas receptor (CD95), we determined whether BCR ± ABL aorded protection against cell death induced by a cross-linking anti-Fas antibody (Ogasawara et al., 1993) . No enhanced survival compared to parental cells was seen in any 3D0-54.8 clones exposed to 1 mg/ml of anti-Fas antibody for 48 h irrespective of their level of BCR ± ABL expression (data not shown). 3D0.bcl2 cells were also not protected against Fas-mediated killing.
Since the CTLL.rv210 and CTLL.bcr210 clones expressed nearly the same amount of BCR ± ABL protein (see Figure 1d and Table 1), they were expected to be similarly resistant to apoptosis. Consistent with this prediction, both CTLL.rv210 and CTLL.bcr210 clones did show signi®cantly increased survival upon treatment with g-radiation or dexamethasone compared to parental CTLL-2 cells ( Figure 5 ). This provided evidence that resistance to apoptosis depended on the level of BCR ± ABL protein expressed, not the vector used. These data also suggested that BCR ± ABL expression in the other myeloid and lymphoid bcr210 clones fell below a critical threshold required for protection against apoptosis.
High levels of BCR ± ABL protect against induction of apoptosis by Ras inactivation
Since Ras is required for the cell survival function of IL-3 (Kinoshita et al., 1995a) , we explored its role in BCR ± ABL-mediated protection against apoptosis. We compared cell survival in FD.bcr210, FD.rv210 and FDC-P1 cell lines stably transfected with a zincinducible vector bearing a mutant ras gene (denoted rasN17) which encodes a dominant ± negative Ras protein (Cook et al., 1993) . Induction of RasN17 was titrated by incubating the cells in medium with increasing concentrations of zinc chloride for 4 days. Expression of RasN17 protein in the presence of 100 ± 150 mM zinc chloride was several-fold higher than that of endogenous Ras (con®rmed in all clones by FACS analysis). Under these conditions, a large proportion (*80%) of FD.bcr210rasN17 and FD.rasN17 cells were killed. Survival of the FD.rv210rasN17 clones was improved (*50%) but protection was not complete (Figure 6 ). Whilst Ras clearly contributed to cell survival in FD.rv210rasN17 clones, their increased survival in the presence of RasN17 may indicate that higher levels of BCR ± ABL recruited additional, Rasindependent anti-apoptotic pathways.
Bcl-2 is induced by high levels of BCR ± ABL
Bcl-2 has been implicated as the protein mediating the protection against apoptosis aorded by cytokines such as IL-2 and IL-3 (Deng and Podack, 1993; Kinoshita et al., 1995a) and by BCR ± ABL (SaÂ nchez-GarcõÂ a and GruÈ tz, 1995; Zhu et al., 1996) . In FDC-P1 cells grown in IL-3, Bcl-2 was detected with a relative¯uorescence intensity approximately tenfold above that of an isotype control antibody. In contrast, Bcl-2 levels were nearly twofold higher in FD.rv210 clones which were resistant to apoptosis (Figure 7a ). We subsequently compared the expression levels of Bcl-2 in bcr210 clones and rv210 clones to levels in parental cells in FDC-P1, M1, 3D0-54.8 and CTLL-2 cell lines. The expression of Bcl-2 ranged from 1.7-to 2.9-fold higher in the rv210 clones in FDC-P1, M1, 3D0-54.8 and CTLL-2 cells, which were resistant to apoptosis ( Figure 7b and Table 4 ). It was pertinent that the only bcr210 clones displaying a similarly elevated level of Bcl-2 expression were the CTLL.bcr210 clones, which were also resistant to apoptosis. FD.bcr210 clones expressed a similar level of Bcl-2 to FDC-P1 cells grown in the presence of IL-3 and showed similar cell survival in response to a range of stimuli. Interestingly, Bcl-2 expression in FD.rasV12 clones grown in the absence of IL-3 was approximately half that found in parental FDC-P1 cells (data not shown), consistent with our ®ndings that FD.rasV12 cells were sensitive to apoptotic stimuli. These experiments demonstrated a strong correlation between the level of Bcl-2 expression and resistance to apoptosis. We noted lower levels of Bcl-2 expression in parental FDC-P1 cells and FD.bcr210 clones 48 h after exposure to 10 Gy of g-radiation. In contrast, the high level of Bcl-2 protein induced by BCR ± ABL in the FD.rv210 clones did not decrease (data not shown). This could be due to the failure of induction of a repressor of Bcl-2, such as p53 (Miyashita et al., 1994; Miyashita and Reed, 1995) , or (more likely) due to the inability of such a protein to override the stimulatory eects of BCR ± ABL on Bcl-2 synthesis.
One possible conclusion from these experiments was that the biological eects of BCR ± ABL in FCD-P1 cells merely re¯ected the combined actions of Bcl-2 and IL-3. However, when we compared the rates of proliferation and survival of irradiated bcr ± abl-and bcl-2-transfected FCD-P1 cell lines, it became apparent that BCR ± ABL was not functionally equivalent to Bcl-2 plus IL-3 (Figure 8 ). During the 5 days after irradiation, the survival of the FD.rv210 clones remained superior to the parental FCD-P1 cells and the FD.bcr210 clones, as we had noted earlier (compare Figure 8a with Figure 3a) . However, although the survival of the FD.rv210 clones was 76 M dexamethasone. The data represents the mean and standard deviation from three experiments comparing three 3D0.bcr210 and three 3D0.rv210 clones with 3D0.bcl2 and parental 3D0-54.8 cells Dose-dependent biological effects of BCR-ABL N Cambier et al consistently inferior to the FD.bcl2 cells, their total cell counts increased after an initial lag of 1 ± 2 days, suggesting that there were dierences in cell cycling after radiation between FD.bcl2 cells grown in IL-3 and FD.rv210 clones (Figure 8b ± c) . We noted similar dierences in the eects of Bcl-2 and BCR ± ABL on the cytokine-independent 3D0-54.8 clones. The survival of the 3D0.bcl2 and 3D0.rv210 clones exposed to radiation or dexamethasone was virtually identical (Figure 4) , but the 3D0.rv210 clones clearly proliferated during the 48 h observation period while the 3D0.bcl2 cultures remained static (data not shown). The initial delay in cell growth we observed in FD.rv210 cells may re¯ect the G2/M arrest induced acutely by irradiation in FDC-P1 or BaF3 cells grown in IL-3 (Collins et al., 1992; Bedi et al., 1995) or expresing BCR ± ABL (Bedi et al., 1995; Nishii et al., 1996) .
Discussion
We hypothesized that the augmented bcr ± abl expression frequently associated with CML disease progression might provide a growth or survival advantage during the evolution of the malignant clone. To test this hypothesis, we expressed BCR ± ABL in factor-dependent and factor-independent myeloid and lymphoid cell lines using the Moloney murine leukemia virus long terminal repeat or the human bcr promoter to direct high or low levels of expression, respectively. Multiple clones were compared from four cell lines to minimise the in¯uence of clonal variation and cellular context on the results. These experiments enabled us to address speci®c questions using lines which diered only in the transduced bcr ± abl expression vector. Did the level of BCR ± ABL protein in¯uence their growth factor requirements or responsiveness, tumorigenicity or response to apoptotic stimuli?
While growth factor-independent lines were readily derived from FDC-P1 cells transfected with either bcr ± abl expression vector, we found that most FD.bcr210 clones increased proliferation in response to IL-3. In contrast, the higher expressing FD.rv210 clones were generally refractory to additional IL-3 stimulation and could proliferate maximally in the absence of this growth factor. These data demonstrated an inverse correlation between the level of BCR ± ABL expression and growth factor responsiveness and predicted that a minimum threshold of expression would be required for cytokine-independent growth. Consistent with this prediction, higher BCR ± ABL expression was observed in CTLL-2 transfectants grown without IL-2 compared to the clones cultured in IL-2 in which there was no selection pressure to maintain a minimum level of BCR ± ABL protein. These studies provided the ®rst experimental evidence that BCR ± ABL could substitute for IL-2 in vitro, although v-abl transformation of an IL-2 dependent T-cell line had been described previously (Cook et al., 1987) . BCR ± ABL had been shown to induce factor-independence in cell lines dependent upon other cytokines such as IL-3, GM-CSF or IL-7 (Daley and Baltimore, 1988; Hariharan et al., 1988; Young et al., 1991) , possibly by mimicking the tyrosine kinases that were normally activated following ligand binding to the receptors for these cytokines. Experiments are in progress to investigate Although cytokine independence was observed in immortalized cell lines expressing BCR ± ABL, the expression of this protein was not the sole criterion which limited factor-independent growth in primary hematopoietic cells. In previous experiments, we derived mast cell lines expressing high levels of BCR ± ABL which initially grew slowly in vitro and were dependent on a stromal layer for growth (Elefanty and Cory, 1992) . Similar results were reported by Gishizky and Witte (1992) who observed that hematopoietic precursors infected with a bcr ± abl retrovirus were hyperresponsive to growth factors but not factor independent. Therefore, it may be that BCR ± ABL has subtle eects on the growth factor requirements of chronic phase CML cells which are not readily discernible in vitro, since primary CML cells express low levels of BCR ± ABL and lack thè complementing' mutations which immortalized lines such as FDC-P1 or CTLL-2.
Interestingly, FD.bcr210 and FD.rv210 clones were equally tumorigenic, suggesting that the in vivo milieu adequately compensated for the dierences in growth which were evident in vitro. The FD.rasV12 clones, which were highly tumorigenic despite poor growth without IL-3 in vitro further underscored the imperfect correlation between in vitro growth and tumorigenicity in vivo.
Recently, attention has focussed on the role that BCR ± ABL may play in protecting cells against apoptosis. BCR ± ABL expression protected immortalized murine cell lines from apoptosis caused by growth factor withdrawal, irradiation, serum deprivation or exposure to cytotoxic agents (Bedi et al., 1994 (Bedi et al., , 1995 McGahon et al., 1994; Cortez et al., 1995; Nishii et al., 1996) . However, CML progenitor cells generally were not more resistant to these stimuli than normal precursors (Amos et al., 1995; Albrecht et al., 1996) , although these ®ndings have been disputed (Bedi et al., 1994 (Bedi et al., , 1995 . In the studies in mouse cells, BCR ± ABL expression was controlled by strong retroviral promoter sequences. The level of BCR ± ABL expression was not documented for the primary CML samples analysed, but these most probably expressed the protein at low levels.
Our observations that resistance to apoptosis critically depended upon the level of BCR ± ABL protein could help to explain a greater sensitivity of primary CML cells to apoptotic stimuli compared to murine cell lines expressing BCR ± ABL. Since survival of FD.bcr210 clones paralled that of parental cells maintained in IL-3 following exposure to ionising radiation, serum deprivation or the kinase inhibitor staurosporine, a low level of BCR ± ABL could be considered solely as a surrogate for IL-3, mimicking both its proliferative and anti-apoptotic eects (Collins et al., 1992) . The elevated BCR ± ABL expression in the Relative¯uorescence intensity in arbitrary units of cytoplasmic Bcl-2 protein derived from¯ow cytometry. Results represent the endogenous levels present in parental cells (con) and the mean and standard deviation of three clones carrying the MPZen (bcr ± abl) retrovirus (rv210) or the bcr ± bcr ± abl expression vector (bcr210).
b Ratio of relativē uorescence intensity for rv210 clones and bcr210 clones compared to parental cells (rv210:con and bcr210:con) and rv210 clones compared to bcr210 clones (rv210:bcr210).
c The rv210 and bcr210 data were compared using a t-Test. The probability of the results being dierent is indicated. NS, not signi®cant a b c FD.rv210 clones allowed the survival of a substantially greater proportion of cells exposed to the same apoptotic stimuli, suggesting that additional survival pathways were activated. Experiments with M1, 3D0-54.8 and CTLL-2 bcr ± abl-transfectants enabled us to extend the dose-dependent eects of BCR ± ABL on cell survival to lymphoid as well as myeloid cells and to cells that were not cytokine-dependent. In the case of M1 and 3D0-54.8 cells, increased BCR ± ABL protein content between bcr210 and rv210 clones also translated into marked increases in protection against apoptosis. The CTLL-2 bcr ± abl cell lines were particularly informative since both bcr210 and rv210 clones expressed BCR ± ABL at nearly the same level and led to similar degrees of protection against apoptosis for both sets of clones. We explored the role of Ras as a mediator of the anti-apoptotic eects of BCR ± ABL through studies with FDC-P1 clones expressing either activated or dominant ± negative mutants of Ha-ras. Other workers have found that expression of activated ras genes in IL-3-dependent cell lines has either reduced or abrogated requirements for exogenous growth factor (Andrejauskas and Moroni, 1989; Boswell et al., 1990; Baker et al., 1994; DumeÂ nil et al., 1994; Kinoshita et al., 1995b; Terada et al., 1995) . In our experiments, expression of activated Ras was sucient to permit sustained growth of FD.rasV12 clones in the absence of IL-3 but did not confer protection against other apoptotic stimuli. In fact, we found that FD.rasV12 cells grew more slowly and were more sensitive to apoptotic stimuli than parental FDC-P1 cells grown in IL-3 or FD.bcr210 cells. As shown in Figure 3 , the addition of IL-3 restored the survival of FD.rasV12 clones exposed to radiation or deprived of serum to that of control cells, which demonstrated that IL-3 (and low levels of BCR ± ABL) did more than just activate ras-dependent pathways. Indeed, it has been shown that both IL-3 and BCR ± ABL induced expression of c-myc and that BCR ± ABL-mediated growth factor independence and transformation were c-myc dependent (Cleveland et al., 1989; Sawyers et al., 1992; Afar et al., 1994) .
The studies with an activated Ras oncogene demonstrated that Ras alone was not sucient for protection against apoptosis in FCD-P1 cells, but did not address whether Ras was actually necessary for BCR ± ABL mediated protection. Therefore, the eects of introduction of an inducible dominant-negative Ras protein (RasN17) into FDC-P1, FD.bcr210 and FD.rv210 cells were compared. It transpired that the survival of FD.rv210rasN17 clones after RasN17 induction was better than either FD.rasN17 clones grown in IL-3 or FD.bcr210rasN17 clones (Figure 6 ). The protection aorded by the higher levels of BCR ± ABL in FD.rv210rasN17 clones, however, was only partial. The interpretation of these data that we favour is that low levels of BCR ± ABL stimulated the same Ras-dependent survival signals as IL-3, but that there were additional anti-apoptotic pathways only activated by high levels of BCR ± ABL. Likely candidates include phosphatidylinositol-3 kinase, a molecule activated by BCR ± ABL which plays an important role in cell survival (Skorski et al., 1995; Franke et al., 1997) or the recently described pathway from Shc to Myc (Gotoh et al., 1996) . An alternative interpretation of the data is that the amount of RasN17 protein induced was insucient and that residual Ras activation by high levels of BCR ± ABL allowed the FD.rv210rasN17 clones to survive, even though we achieved the expression levels of RasN17 that are believed to completely block Ras signalling (Farnsworth and Feig, 1991; de Vries-Smits et al., 1992) . Recently, Cortez et al. (1996) concluded that Ras was necessary for BCR ± ABL-mediated inhibition of apoptosis because introduction of RasN17 into BCR ± ABLtransformed 32D cells led to apoptosis in *60% of cells. Actually, this result was similar to the *50% survival we observed in our FD.rv210rasN17 clones. However, Cortez et al. did not compare the survival of 32D cells transduced with RasN17 in the absence of BCR ± ABL (equivalent to our FD.rasN17 clones), so they could not address the possibility that coexpression of BCR ± ABL provided partial protection and enhanced the proportion of cells surviving in the presence of RasN17.
It has been argued that Bcl-2 mediates the antiapoptotic eects of BCR ± ABL (SaÂ nchez-GarcõÂ a and GruÈ tz, 1995; Zhu et al., 1996) . SaÂ nchez-GarcõÂ a and GruÈ tz (1995) showed that BaF3 cells transfected with bcr ± abl expressed bcl-2 mRNA and that anti-sense bcl-2 abrogated the protective eects of BCR ± ABL against IL-3 deprivation. Zhu et al. (1996) demonstrated increased amounts of Bcl-2 protein in cell lysates derived from bcr ± abl transfected 32D cells compared to parental cells. Consistent with these data, we found an excellent correlation between the amount of BCR ± ABL protein, the level of Bcl-2 induction and the degree of resistance to apoptosis (compare Figure  1c and Figure 7) . A previous study reported that expression of an activated Ras gene induced bcl-2 mRNA in 32D cells to nearly the same level as seen in cells growing in IL-3 (Kinoshita et al., 1995b) . In our FD.rasV12 clones, the level of Bcl-2 protein was only half that of parental cells grown in IL-3 (data not shown) and their resistance to apoptosis was correspondingly diminished. In relating these observations to CML, it is relevant that increased Bcl-2 expression was found in only 1/7 bone marrow samples from chronic phase CML, but in 3/3 bone marrow samples from patients with CML in blast crisis (Delia et al., 1992) . Therefore, it is tempting to speculate that a correlation may exist between expression of BCR ± ABL and Bcl-2 in primary CML cells, similar to our ®ndings in cell lines.
In the light of the experimental results described here, the biological consequences accompanying high and low levels of BCR ± ABL may be correlated with the activation of distinct signalling pathways. Conceptually,`cytokine-like' signalling cascades, exempli®ed by Ras/MAPK pathways and Myc activation, may be activated by low levels of BCR ± ABL, leading to growth factor independence in immortalized cells.`Bcl-2-like' anti-apoptotic mechanisms, which protect against stimuli such as ionizing radiation, are dependent upon high levels of BCR ± ABL. Currently, the only identi®ed cell survival molecule induced by BCR ± ABL is Bcl-2 and altered expression of its homologue, Bcl-x or its antagonist, Bax has not been observed (Nishii et al., 1996; Zhu et al., 1996) . However, our experiments suggested that the induction of other proteins was necessary to explain the complex eects of BCR ± ABL on survival and proliferation ( Figure 8) . A detailed understanding of the biology of BCR ± ABL will require the identification of additional proteins impacting on cell survival and/or proliferation.
Materials and methods
Plasmids
The MPZen(bcr ± abl) retroviral vector has been described previously (Hariharan et al., 1988) . The bcr ± bcr ± abl vector was constructed by ligating a 6 kb genomic fragment from the human bcr gene (plasmid pJJ-22, a gift from Dr J Groen) which included approximately 4.5 kb of the bcr promoter, the 5' untranslated region and the ®rst 200 amino acids (up to the XhoI site) of bcr exon I, to the remainder of the bcr ± abl cDNA (Daley et al., 1987) . The second intron and polyadenylation sequence from the rabbit b globin gene (Severne et al., 1988) was cloned downstream of the bcr ± abl termination codon. The activated Ha-ras (p21 H-ras (val12)) expression vector (pEXV KT) (Hancock et al., 1989) and the inducible dominant negative ras vector (pM 2 NrasN17) (Cook et al., 1993) were gifts from Dr S Cook and the pPGKpuro plasmid was a gift from Dr S Cory.
Cell lines
FDC-P1 cells (Dexter et al., 1980) were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) containing 10% (v/v) fetal calf serum (FCS) and 10% WEHI-3B (Metcalf, 1979) conditioned medium as a source of interleukin 3 (IL-3). M1 cells (Metcalf et al., 1988) were grown in DMEM/10% FCS. CTLL-2 cells (Cerottini et al., 1974) and 3D0-54.8 cells (Haskins et al., 1983) were grown in DMEM/10% FCS supplemented with 10 mM HEPES, 22 mM glucose, 2 mM glutamine, 0.5 mM arginine, 0.3 mM asparagine, 120 mM folic acid and 50 mM 2-mercaptoethanol. Supernatant from the hybridoma X-63Ag8 mIL-2 (Karasuyama and Melchers, 1988) was included as a source of interleukin 2 (IL-2) in CTLL-2 cultures.
BCR ± ABL-and RasV12-expressing cell lines were generated by co-transfection of parental cells with linearised bcr ± abl or pEXV KT plasmids and puromycin resistance plasmids in a 10 : 1 molar ratio. A BioRadGene Pulser (BioRad Laboratories, CA, USA) was used at 270 volts and 960 mF. Each transfection was divided into 6 ± 12 independent pools prior to selection with puromycin (Sigma Chemicals St Louis, MO, USA) 48 h post-electroporation at a concentration of 2 mg/ml for FDC-P1, 20 mg/ml for M1, 1.25 mg/ml for 3D0 and 5 mg/ml for CTLL-2 cells. FDC-P1 cells transfected with pM 2 NrasN17 plasmid were selected in 800 mg/ml G418 (Geneticin, GibcoBRL, NY, USA). CTLL-2 and FDC-P1 cells expressing BCR ± ABL and FDC-P1 cells expressing RasV12 were subsequently selected for growth factor independence. The cells were washed three times in PBS and then resuspended in the original medium without addition of growth factor. Pools of proliferating cells visible 8 ± 15 days later were tested for BCR ± ABL or Ras expression using¯ow cytometry. BCR ± ABL expression was also determined in CTLL-2 transfectants maintained in IL-2. Cell lines were cloned by limiting dilution or by expanding single colonies grown in soft agar as described (Metcalf, 1977) .
Biological assays
Conditioned medium from factor-independent cell lines was concentrated 20-fold and assayed for granulocytemacrophage colony-stimulating factor (GM-CSF), IL-3 and IL-2 activity using recombinant factors of known concentration as controls in microwell cultures as previously described (Metcalf et al., 1995) . FDC-P1 cell lines were grown in agar in the presence or absence of 10 3 U/ml IL-3 for 7 days and average cell numbers per colony calculated from pools of dispersed plucked colonies.
Survival assays
Cell viability was determined by eosin exclusion and counting of live and dead cells in a hemocytometer or bȳ ow cytometric analysis of propidium iodide-stained cells using a FACScan (Becton Dickinson, Mountain View, CA). Cells were treated with 1 mM dexamethasone, 1 mg/ml anti-Fas antibody (mAb Jo-2, Pharmingen, San Diego, CA, USA), 100 nM staurosporine (Sigma Chemicals) or girradiation from a 60 Co source and survival assessed when indicated in the ®gure legends. Serum deprivation was performed by washing the cells three times in PBS and resuspending them in medium containing either 0.5% FCS (for FDC-P1 clones) or 0.1% FCS (for M1 clones). Cells transfected with pM 2 NrasN17 were maintained in DMEM containing zinc-depleted FCS. To induce RasN17, cells were grown in medium supplemented with 50 ± 200 mM ZnCl 2 for 4 days and cell survival was estimated. Gene induction was con®rmed by¯ow cytometry using the antiRas Y 13-259 antibody (Oncogene Science, Uniondale NY, USA). Optimal results were obtained with 100 ± 150 mM ZnCl 2 and higher concentrations were associated with nonspeci®c toxicity.
Immuno¯uorescence and¯ow cytometry
Staining of cell lines by indirect immuno¯uorescence was as previously described (Antoniou et al., 1993) . Brie¯y, cells were ®xed for 10 min at 48C in 3.7% paraformaldehyde in CSK buer (10 mM PIPES, pH 6.8, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl 2 , 2 mM EGTA) and permeabilised in 0.5% Triton X-100/CSK for 15 min prior to antibody staining. Images were captured as single optical sections on a Leica confocal laser scanning microscope (Leica Lasertechnik, Heidelberg, Germany) and processed with the SCANWARE software package. For¯ow cytometric detection of BCR ± ABL, murine Bcl-2 and Ras proteins, cells were ®xed for 10 min in 1% paraformaldehyde at room temperature and permeabilized with 0.3% saponin (Sigma Chemicals) as described (Strasser et al., 1995) . The cells were stained with monoclonal antibodies against ABL (mouse monoclonal 24-21; Oncogene Science), mouse Bcl-2 (hamster monoclonal 3F11; Pharmingen) or Ras (rat monoclonal Y 13-259; Oncogene Science) using FITC-conjugated goat antimouse or anti-rat IgG (Southern Biotechnology, Birmingham AL, USA) or FITC-conjugated mouse anti-hamster IgG (Pharmingen) antibodies as secondary reagents.
Tumorigenesis
DBA/2 mice, 5 ± 8 weeks of age, were injected intravenously with 5610 5 cells from the parental FDC-P1 cell line and four clones each of FD.bcr210, FD.rv210 and FD.rasV12. Each clone was injected into 3 ± 4 recipient mice. Sick mice were autopsied, organ samples were taken for histology and spleen cells were cultured in DMEM/ 10% FCS to recover tumour cells.
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